NCT00691015 · OUTCOME

Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment.

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant · Source last updated 2017-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: % of participants with a reported SAE
Interval / dispersion: 95% Confidence Interval
Time frame: Within 6 months after PBSCT

Analysis population: All participants

Groups in this outcome

All Participants

All regimens were analyzed together.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Participants	47

Reported measurements

Source class 1

Values in % of participants with a reported SAE · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Participants	93.62	Not reported	82.46	98.66	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
82.46
upper Limit
98.66
value
93.62

denoms

counts
group Id
OG000
value
47
units
Participants

dispersion Type

95% Confidence Interval

groups

description
All regimens were analyzed together.
id
OG000
title
All Participants

param Type

NUMBER

population Description

All participants

reporting Status

POSTED

time Frame

Within 6 months after PBSCT

title

Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment.

type

PRIMARY

unit Of Measure

% of participants with a reported SAE

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice